Optimized strategies for introducing new antibiotics in healthcare to preserve patient safety and counteract emergence of resistance
( INTRODUCE )
Interventions
Surveillance
Therapeutics
Research Project: 2025-04-01 - 2028-03-31
Total sum awarded: €736 425
- Thomas Tängdén, Uppsala University, Sweden (Coordinator)
- Stephan Harbarth, University of Geneva, Switzerland (Partner)
- Pilar Retamar-Gentil, Institute Biosanitario de Sevilla, Spain (Partner)
- Dafna Yahav, Sheba medical center, Israel (Partner)
- Mona Hellou Mustafa, Rambam Health Care Campus, Israel (Partner)
- Elena Carrara, University of Verona, Italy (Observer)
The slow research and development of new antibiotics is insufficient to counteract the rapid emergence and spread of multidrug-resistant bacteria. Yet, approaches for how newly approved antibiotics are introduced in healthcare vary greatly across countries. This could lead to disparity regarding the availability and use of the new antibiotics in healthcare and create inequality with regard to chances of treating difficult-to treat infections. Because antibiotics is a shared resource, excessive use a new antibiotic in one country will accelerate development of resistance and shorten the lifespan of this antibiotics in all countries.